Why the study?
What are the plasma levels and pharmacodynamics of trinitroglycerin administered via different routes?
What are the plasma levels and pharmacodynamics of trinitroglycerin administered via different routes?
A newly developed assay for trinitroglycerin in human plasma demonstrates similar maximum plasma levels across intravenous, transcutaneous, and sublingual administration routes, highlighting the need for individualized therapy due to wide dose ranges.
Comparable levels may allow flexible nitroglycerin dosing; extends pharmacokinetic data but leaves outcome effects open.
We developed a simplified method for quantitative measurement of trinitroglycerin in human plasma using hexane extraction and analysis by gas-liquid chromatography with electron-capture detection. This assay was linear from 0.5-60 ng/ml. Sensitivity and reproducibility were +/- 0.5 ng/ml. We used this assay to evaluate the pharmacodynamics of trinitroglycerin in 14 patients. Maximum plasma levels were similar with trinitroglycerin given by constant intravenous infusion (1.6 +/- 0.4 ng/ml (SEM)), transcutaneously (2.3 +/- 0.6 ng/ml), or sublingually (1.6 +/- 0.6 ng/ml). Despite similar levels and hemodynamic responses after intravenous trinitroglycerin, the dose range was wide (37.5-175 microg/min, n = 5), emphasizing the need to individualize therapy. In normal volunteers on no other drugs, the plasma level time course followed changes in heart rate better than blood pressure changes. Use of the trinitroglycerin assay may enhance optimization of trinitroglycerin therapy when administered by different methods.
No takes yet. Share an insight, caveat, or question.
Wei et al. (1979) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: